{
  "case_id": "Case_4",
  "model_id": "cohere/command-r-plus",
  "content": "{\n    \"primary_diagnosis\": {\n        \"name\": \"Muscular Dystrophy, Limb-Girdle Type 2A (LGMD2A or Calpainopathy)\",\n        \"confidence\": 0.75,\n        \"icd_code\": \"G72.3\",\n        \"reasoning\": \"The patient's symptoms of exercise intolerance, intermittent muscle weakness, and elevated CK levels during episodes are highly suggestive of a muscular dystrophy. The consanguinity of the parents and the patient's limited social interactions also point towards a rare genetic disorder. LGMD2A is a form of muscular dystrophy that typically presents in adolescence with proximal muscle weakness and elevated CK levels. It is caused by mutations in the CAPN3 gene, and consanguinity is a known risk factor for this disorder.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"McArdle Disease (GSD V, Glycogen Storage Disease Type V)\",\n            \"confidence\": 0.6,\n            \"icd_code\": \"E74.0\",\n            \"reasoning\": \"McArdle disease is a metabolic myopathy characterized by exercise intolerance, muscle pain, and elevated CK levels. The patient's episodes of muscle weakness and dark urine after intense exercise are indicative of potential metabolic abnormalities, which are key features of McArdle disease.\"\n        },\n        {\n            \"name\": \"Periodic Paralysis, Hypokalemic\",\n            \"confidence\": 0.5,\n            \"icd_code\": \"G73.0\",\n            \"reasoning\": \"Hypokalemic periodic paralysis is a channelopathy that can present with episodes of muscle weakness and pain after intense exercise. The fluctuation in symptom severity and the presence of triggers such as intense exercise are key features of this disorder.\"\n        },\n        {\n            \"name\": \"Mitochondrial Myopathy\",\n            \"confidence\": 0.4,\n            \"icd_code\": \"G73.89\",\n            \"reasoning\": \"Mitochondrial myopathies are a group of rare genetic disorders that can present with exercise intolerance, muscle weakness, and elevated CK levels. The variability in symptoms and potential multisystem involvement make mitochondrial myopathies an important consideration in this case.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Elevated CK levels during episodes\",\n        \"Consanguineous parents\",\n        \"Limited social interactions\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"Genetic Testing (CAPN3 gene analysis)\",\n            \"purpose\": \"Confirm diagnosis of LGMD2A\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Muscle Biopsy\",\n            \"purpose\": \"Evaluate for muscular dystrophy and metabolic myopathies\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Electromyography (EMG) and Nerve Conduction Studies (NCS)\",\n            \"purpose\": \"Assess for myopathic or neuropathic processes\",\n            \"priority\": \"routine\"\n        },\n        {\n            \"test\": \"Cardiac Evaluation (ECG, Echocardiogram)\",\n            \"purpose\": \"Evaluate for cardiac involvement, as some muscular dystrophies can affect the heart\",\n            \"priority\": \"routine\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Referral to a pediatric neurologist with expertise in neuromuscular disorders\",\n            \"Genetic counseling for the patient and family to discuss the potential impact of consanguinity on future offspring\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Nonsteroidal Anti-inflammatory Drugs (NSAIDs)\",\n                \"dose\": \"Standard doses\",\n                \"route\": \"PO\",\n                \"duration\": \"As needed for muscle pain\",\n                \"rationale\": \"To manage muscle pain and inflammation\"\n            }\n        ],\n        \"monitoring\": [\n            \"Regular neurological assessments to monitor for progression of muscle weakness\",\n            \"Repeat CK levels during and between episodes to assess disease activity\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Medical Genetics\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"To confirm the genetic basis of the disorder and provide genetic counseling\"\n            },\n            {\n                \"specialty\": \"Pediatric Neurology\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"For further evaluation and management of neuromuscular disorder\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Rapid progression of muscle weakness\",\n        \"Cardiac involvement, as some muscular dystrophies can affect the heart\"\n    ],\n    \"patient_education\": [\n        \"Explanation of the diagnosis and its genetic basis\",\n        \"Importance of regular neurological follow-up and monitoring\",\n        \"Strategies to manage exercise and physical activity to prevent exacerbations\",\n        \"Signs and symptoms of cardiac involvement to monitor for\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"3 months\",\n        \"conditions\": \"Return sooner if there is a rapid progression of symptoms, development of cardiac symptoms, or new concerning features.\"\n    },\n    \"confidence_in_assessment\": 0.7,\n    \"uncertainties\": [\n        \"The exact genetic basis of the disorder in this patient may vary, and further genetic testing is required for confirmation.\",\n        \"The impact of consanguinity on the expression of the disorder in this patient is uncertain and may vary depending on the specific genetic mutations involved.\"\n    ]\n}",
  "latency": 27.532378911972046,
  "timestamp": "2025-08-10T01:15:44.658971",
  "cached_at": "2025-08-10T01:15:44.658978"
}